Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome.

Gulseth HL, Gjelstad IM, Tierney AC, Lovegrove JA, Defoort C, Blaak EE, Lopez-Miranda J, Kiec-Wilk B, Risérus U, Roche HM, Drevon CA, Birkeland KI.

Diabetes Care. 2010 Apr;33(4):923-5. doi: 10.2337/dc09-1692. Epub 2010 Jan 12. Erratum in: Diabetes Care. 2010 Dec;33(12):2725. Ris, Ulférus [corrected to Risérus, Ulf].

2.

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.

Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R; NBI-6024 Study Group.

Diabetes Care. 2009 Nov;32(11):2036-40. doi: 10.2337/dc09-0449. Epub 2009 Aug 18.

3.

Vitamin D levels in subjects with and without type 1 diabetes residing in a solar rich environment.

Bierschenk L, Alexander J, Wasserfall C, Haller M, Schatz D, Atkinson M.

Diabetes Care. 2009 Nov;32(11):1977-9. doi: 10.2337/dc09-1089. Epub 2009 Aug 12.

4.

Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk.

Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pflüger M, Illig T, Bonifacio E, Ziegler AG.

Diabetologia. 2009 Sep;52(9):1881-8. doi: 10.1007/s00125-009-1438-0. Epub 2009 Jul 10.

PMID:
19590848
5.

Vitamin D: emerging new roles in insulin sensitivity.

Teegarden D, Donkin SS.

Nutr Res Rev. 2009 Jun;22(1):82-92. doi: 10.1017/S0954422409389301. Review.

PMID:
19555519
6.

Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).

Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z.

Diabetes Metab Res Rev. 2009 Jul;25(5):411-6. doi: 10.1002/dmrr.977.

PMID:
19488999
7.

Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis.

Zipitis CS, Akobeng AK.

Arch Dis Child. 2008 Jun;93(6):512-7. doi: 10.1136/adc.2007.128579. Epub 2008 Mar 13. Review.

PMID:
18339654
8.

Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Staeva-Vieira T, Peakman M, von Herrath M.

Clin Exp Immunol. 2007 Apr;148(1):17-31. Review. Erratum in: Clin Exp Immunol. 2007 Jul;149(1):203.

9.

1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells.

Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, Adorini L.

J Immunol. 2007 Jan 1;178(1):145-53.

10.

The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI).

Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group.

Diabet Med. 2006 Aug;23(8):920-3.

PMID:
16911633
11.

Vitamin D and diabetes.

Mathieu C, Gysemans C, Giulietti A, Bouillon R.

Diabetologia. 2005 Jul;48(7):1247-57. Epub 2005 Jun 22. Review.

PMID:
15971062
12.

1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice.

Gysemans CA, Cardozo AK, Callewaert H, Giulietti A, Hulshagen L, Bouillon R, Eizirik DL, Mathieu C.

Endocrinology. 2005 Apr;146(4):1956-64. Epub 2005 Jan 6.

PMID:
15637289
13.
14.

Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3).

van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C.

Diabetes. 2002 Jul;51(7):2119-25.

15.

Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3.

Gysemans C, Van Etten E, Overbergh L, Verstuyf A, Waer M, Bouillon R, Mathieu C.

Clin Exp Immunol. 2002 May;128(2):213-20.

16.

A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice.

Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L.

Diabetes. 2002 May;51(5):1367-74.

17.

Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.

Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM.

Lancet. 2001 Nov 3;358(9292):1500-3.

PMID:
11705562
18.

1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.

Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A.

J Immunol. 2001 Nov 1;167(9):4974-80.

19.

Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Atkinson MA, Eisenbarth GS.

Lancet. 2001 Jul 21;358(9277):221-9. Review. Erratum in: Lancet. 2001 Sep 1;358(9283):766.

PMID:
11476858
20.

Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo.

Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R.

Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6800-5. Epub 2001 May 22.

Items per page

Supplemental Content

Write to the Help Desk